South Korean Lawmaker Introduces Medical Cannabis Production Bill

Bill Filed in National Assembly

The measure was filed in South Korea's National Assembly on July 10, 2026, according to parliamentary records. The bill's sponsor hasn't been publicly identified in initial reports. The legislative text hasn't yet been posted to the Assembly's online database. South Korea operates a unicameral legislature with 300 seats; bills typically require committee review, plenary debate, and presidential assent to become law.

The filing follows years of incremental policy shifts. South Korea legalized the importation and prescription of cannabis-derived medicines in March 2019, making it the first East Asian nation to permit any form of medical cannabis access. That framework, however, prohibits domestic cultivation, processing, or manufacture. Patients may access only foreign-produced pharmaceuticals approved by the Ministry of Food and Drug Safety—primarily cannabidiol formulations for epilepsy and cancer-related symptoms.

The new legislation would remove the import-only restriction. If enacted, South Korean entities could apply for licenses to grow cannabis plants and extract active compounds for pharmaceutical use within the country's borders.

Current Legal Framework and Patient Access

Under existing law, South Korean patients may obtain medical cannabis only through a physician's prescription and only for conditions the Ministry of Food and Drug Safety has approved. The ministry maintains a narrow list of qualifying diagnoses, including rare epilepsy syndromes and chemotherapy-induced nausea. Physicians must submit detailed justification for each prescription. Patients face frequent re-authorization requirements.

Importation is restricted to products that meet pharmaceutical-grade manufacturing standards in their country of origin. The ministry has approved fewer than a dozen cannabis-based medicines since 2019, all of them manufactured in Canada, the United Kingdom, or the United States. Domestic patient advocates have criticized the system as expensive and logistically cumbersome, citing long wait times for import approvals and high out-of-pocket costs that aren't covered by South Korea's national health insurance.

Cannabis possession, cultivation, and distribution remain criminal offenses under South Korea's Narcotics Control Act. Penalties include prison sentences of up to five years for possession and up to life imprisonment for large-scale trafficking. The law applies extraterritorially to South Korean citizens who use cannabis abroad, though enforcement of overseas conduct is inconsistent.

Scope of Proposed Production Regime

Details of the proposed licensing structure, cultivation limits, and quality-control requirements aren't yet public. Parliamentary procedure in South Korea requires that bill text be published within days of filing, but as of July 10 the measure hadn't appeared in the Assembly's legislative management system. The bill's scope will determine whether it permits only pharmaceutical-grade extraction facilities or also allows agricultural cultivation by licensed farms.

International precedent suggests several models. Canada's Access to Cannabis for Medical Purposes Regulations, introduced in 2013, created a licensed-producer system with seed-to-sale tracking and mandatory laboratory testing. Israel's medical cannabis program, operational since the 1990s, licenses both cultivation and manufacturing under the Ministry of Health's oversight, with production quotas tied to patient enrollment.

South Korea's regulatory environment is generally risk-averse. The Ministry of Food and Drug Safety enforces stringent good manufacturing practice standards for all pharmaceuticals. The Ministry of Agriculture, Food and Rural Affairs maintains tight controls on controlled-substance precursors. Any domestic cannabis production framework would likely require multi-agency coordination and extensive compliance infrastructure.

Political and Cultural Context

South Korea's conservative political culture and strict drug-enforcement posture make cannabis policy reform a high-risk legislative effort. Public opinion polling in 2024 found that 62 percent of South Koreans opposed legalization of recreational cannabis, though support for medical access has risen modestly since the 2019 import law took effect. The ruling People Power Party, which holds a narrow majority in the National Assembly, hasn't taken a formal position on medical cannabis production.

The opposition Democratic Party of Korea has historically supported incremental drug-policy reform, including harm-reduction measures for opioid addiction. But no major party has endorsed broader cannabis liberalization. South Korea's prosecutorial and law-enforcement agencies wield significant political influence. They've consistently opposed any expansion of legal cannabis access.

Regional dynamics also matter. No other East Asian government permits domestic cannabis cultivation for any purpose. Japan allows limited research cultivation under strict academic licenses but prohibits medical use. China permits industrial hemp cultivation for fiber and seed but classifies cannabis flower as a controlled narcotic. Taiwan's legislature rejected a medical cannabis bill in 2020 after opposition from the Ministry of Justice.

Economic and Industry Implications

If enacted, the bill would create South Korea's first legal cannabis supply chain, opening opportunities for pharmaceutical manufacturers, agricultural technology firms, and logistics providers. South Korea's pharmaceutical sector generated $24.3 billion in revenue in 2025, according to the Korea Pharmaceutical Manufacturers Association, with a significant focus on biologics and biosimilars. Cannabis-derived active pharmaceutical ingredients could fit within that manufacturing base, though the scale would depend on patient enrollment and approved indications.

South Korea's agricultural sector has faced declining farm income and rural depopulation for two decades. Specialty crops with high per-acre value—including ginseng and medicinal herbs—have been promoted as economic-development tools. Cannabis cultivation could offer similar returns. The crop's controlled-substance status would require security measures and regulatory oversight far exceeding those for conventional agriculture.

No South Korean company has publicly announced plans to enter the medical cannabis sector. In contrast, Canadian licensed producers and Israeli cultivators have established export-focused operations that supply South Korea's current import market. Domestic production would shift revenue from foreign suppliers to South Korean entities, though the total market size remains small given the restrictive patient-access rules.

Legislative Path and Timeline

The bill must clear committee review, plenary votes, and presidential approval before becoming law. South Korea's National Assembly assigns bills to standing committees based on subject matter. This measure would likely go to the Health and Welfare Committee, which has jurisdiction over pharmaceutical regulation, or the Agriculture, Food, Rural Affairs, Oceans and Fisheries Committee, which oversees controlled agricultural substances. Committee chairs have discretion to schedule hearings or let bills languish without action.

If the committee advances the bill, it proceeds to a plenary vote. A simple majority of members present is required for passage, assuming a quorum of at least 150 members. The president then has 15 days to sign or veto the legislation. A presidential veto can be overridden by a two-thirds supermajority in the Assembly.

South Korea's legislative calendar runs from June through May, with summer and winter recess periods. The current session, which opened in June 2026, will conclude in May 2027. Bills that don't pass before the session ends must be reintroduced in the next session. Given the measure's novelty and the absence of strong political champions, passage in the current session is uncertain.

What Comes Next

The bill's text, sponsor identity, and committee assignment should become public within the next week as the National Assembly updates its legislative database. Patient advocacy groups and pharmaceutical industry associations will likely submit position statements once the bill's details are known. The Ministry of Food and Drug Safety and the Ministry of Justice will be asked to provide technical assessments during committee review.

For more background on South Korea's medical cannabis policy evolution, see the CannIntel topic hub on South Korea medical cannabis. The next procedural milestone will be the committee referral, which typically occurs within two weeks of filing. If the bill receives a hearing, witness testimony and agency input will clarify the government's stance.